Polar Asset Management Partners’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Polar Asset Management Partners’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-616,700	Closed	-$6.23M	–	1329
2022 Q4	$6.23M	Buy	616,700 +50,000	+9%	+$501K	0.08%	358
2022 Q3	$5.62M	Hold	566,700	–	–	0.07%	438
2022 Q2	$5.61M	Hold	566,700	–	–	0.07%	435
2022 Q1	$5.59M	Sell	566,700 -382	-0.1%	-$3.76K	0.06%	400
2021 Q4	$5.58M	Sell	567,082 -32,918	-5%	-$323K	0.06%	381
2021 Q3	$5.84M	Hold	600,000	–	–	0.06%	362
2021 Q2	$5.8M	Hold	600,000	–	–	0.06%	341
2021 Q1	$5.83M	Buy	+600,000	New	+$5.81M	0.06%	299

Polar Asset Management Partners's BIOT Position: Q1 2023 in Review

Polar Asset Management Partners sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 616,700 shares — an estimated $6.23M sold.

Polar Asset Management Partners first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $6.23M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Polar Asset Management Partners reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Polar Asset Management Partners sold 616,700 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $6.23M.
Polar Asset Management Partners first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
Polar Asset Management Partners's Biotech Acquisition Company Class A Ordinary Shares position peaked at $6.23M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Polar Asset Management Partners's 13F filing for Q1 2023, filed 15 May 2023.